FineHeart
FineHeart develops FlowMaker®, an implantable intracardiac pump designed to treat advanced heart failure by augmenting the patient's native ejection fraction on each cardiac cycle. The device combines mechanical, electronic, and automatic engineering disciplines into a single Active Implantable Medical Device (AIMD) intended for long-term implantation. The company is currently at clinical stage, positioning the device as a new treatment option for the roughly 90% of severe heart failure patients who lack efficient existing therapies.
- Medical Devices
- Healthcare Technology
- Hardware
Funding
Raised to date
€62.4MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Est. $68Macross 4 rounds
+7€35M · Series C
Announced Jan 2026 · from article date
Disclosed cumulative: $68M
Founders
Founder details are not available yet.
Product
Problem
Advanced heart failure affects hundreds of thousands of new patients each year, yet approximately 90% of them have no efficient treatment option. Existing therapies are limited by complications, leaving clinicians unable to propose effective solutions for their patients with severe heart failure.
Solution
FineHeart has developed FlowMaker®, an Intra Cardiac Output Management System (ICOMS) that functions as an implantable intracardiac pump. The device assists patients suffering from severe heart failure by complementing their native ejection fraction on each cardiac cycle. FlowMaker® combines expertise from cardiology with engineering know-how in mechanical, electronic, and automatic systems to provide a breakthrough therapy for advanced heart failure. The company is a clinical-stage medtech developing this solution as a European Active Implantable Medical Device (AIMD), positioning it as a new treatment paradigm for patients who currently lack viable options.
Target Audience
Primary customers are interventional cardiologists and heart failure specialists treating patients with severe heart failure, as well as hospital cardiac surgery and heart failure departments seeking implantable mechanical circulatory support options.
Features
- Implantable intracardiac pump (ICOMS FlowMaker®) that augments native ejection fraction on a per-cardiac-cycle basis
- Combines mechanical, electronic, and automatic engineering disciplines in a single integrated device
- Designed as an Active Implantable Medical Device (AIMD) for long-term implantation in severe heart failure patients
- Clinical-stage technology with recognition including top-graded cardiac abstract and MedTech Innovator finalist status
- Quality management system aligned with ISO 13485 and preparation for FDA compliance (21 CFR)